Current TrialNational Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: Evaluation of Exemestane to Prevent Breast Cancer in Postmenopausal Women
References (35)
- et al.
Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial
Lancet
(1998) - et al.
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study
Lancet
(1998) - et al.
Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view
Clin Breast Cancer
(2001) - et al.
Overview of the main outcomes in breast-cancer prevention trials
Lancet
(2003) - et al.
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
Lancet
(2007) - et al.
Local endocrine effects of aromatase inhibitors within the breast
J Steroid Biochem Mol Biol
(2001) Comparison of in vitro exemestane activity versus other antiaromatase agents
Clin Breast Cancer
(2000)- et al.
Effects of aromatase inhibitors on human osteoblast and osteoblast-like cells: a possible androgenic bone protective effects induced by exemestane
Bone
(2007) - et al.
A menopause-specific quality of life questionnaire: development and psychometric properties
Maturitas
(1996) - et al.
Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies
J Natl Cancer Inst
(2002)
Aromatase inhibitors in breast cancer
N Engl J Med
NOLVADEX® (tamoxifen citrate tablets). Full prescribing information
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study
J Natl Cancer Inst
Tamoxifen in the treatment of breast cancer
N Engl J Med
Prescription of tamoxifen for breast cancer prevention by primary care physicians
Arch Intern Med
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial
JAMA
EVISTA® (raloxifene hydrochloride). Full prescribing information
Cited by (20)
Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers
2017, European Journal of CancerCitation Excerpt :Women with an intact uterus require combination HRT because unopposed oestrogen increases uterine cancer risk, but combined HRT may further increase the risk of breast cancer [36] which is important for BRCA1 and BRCA2 mutation carriers who have a high-background breast cancer risk. Although hysterectomy eliminates the risk of uterine cancer in mutation carriers who choose tamoxifen for treatment or prevention of breast cancer, the use of an aromatase inhibitor instead of tamoxifen is an alternative approach and is not associated with uterine cancer [37–40]. Precisely estimating the true increased risk, if any, of uterine cancer in BRCA1 and BRCA2 mutation carriers will need a large multi-national study or meta-analysis; in the meantime, we do not believe that routine hysterectomy at RRSO is justified in the vast majority of BRCA1 and BRCA2 mutation carriers.
Breast cancer prevention trials: Large and small trials
2010, Seminars in OncologyCitation Excerpt :Secondary endpoints include total incidence of invasive and noninvasive (DCIS) breast cancer and other malignancies with EXE compared to placebo; incidence of hormone receptor–negative invasive breast cancer; incidence of noninvasive/premalignant breast lesions (LCIS, ADH, atypical lobular hyperplasia) and number of clinical breast biopsies; incidence of adverse events, with emphasis on clinical fractures (especially hip and vertebral fractures) and clinically relevant cardiac events; and comparison of quality-of-life measures, as assessed by the Short Form-36 General Health Survey and the Menopause-Specific Quality of Life Questionnaire. Biospecimens also are being collected42 and bone mineral density and annual mammograms are being obtained.42,48 The NCI Canada's Mammary 17 (MA.17) trial used an extended adjuvant design (Figure 1).49
Breast cancer milestones 2007–2016
2017, Memo - Magazine of European Medical OncologyPharmacological prevention of breast cancer
2015, Revisiones en CancerPersonalized therapy for breast cancer
2014, Clinical Genetics
Electronic forwarding or copying is a violation of US and International Copyright Laws.
Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by CIG Media Group, LP, ISSN #1526-8209, provided the appropriate fee is paid directly to Copyright Clearance Center, 222 Rosewood Drive, Danvers, MA 01923 USA 978-750-8400.